FDA approves groundbreaking cell-based gene therapies for Sickle Cell Disease

By Stacy M. Brown NNPA Senior National Correspondent The U.S. Food and Drug Administration (FDA) has greenlit two revolutionary cell-based gene therapies, Casgevy and Lyfgenia, marking a significant leap forward in treating sickle cell disease (SCD) for patients aged 12 and older. The approval by the FDA signifies the commencement of a novel epoch in […] The post FDA approves groundbreaking cell-based gene therapies for Sickle Cell Disease appeared first on North Dallas Gazette.